Drugs / PR1:169-177
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00488592 | Jun 2007 → Apr 2010 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR1:169-177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00488592 ↗ |
| Known as | peptide (PR1:169-177) | “peptide (PR1:169-177)” NCT00488592 ↗ |
| Route | Subcutaneous | “Subjects were given 6 subcutaneous injects of PR1:169-177 in "Montanide" adjuvant and 6 subcutaneous injections of WT1:126-134 in "Montanide" adjuvant at 2 weekly intervals.” NCT00488592 ↗ |